Zai Lab Ltd
09688
Company Profile
Business description
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.
Contact
4560 Jinke Road
Jinchuang Plaza, Building 1, 4th Floor
Pudong
Shanghai201210
CHNT: +86 2161632588
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
1,844
Stocks News & Analysis
stocks
Has the most hated company on the ASX 200 bounced back?
Encouraging results indicate a potential turnaround story.
stocks
Amazon earnings: Good results, with AWS still a winner; fear on profitability guidance is overblown
We think Amazon stock looks attractive.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,903.50 | 95.50 | -1.06% |
| CAC 40 | 7,546.16 | 225.81 | -2.91% |
| DAX 40 | 23,425.97 | 639.50 | -2.66% |
| Dow JONES (US) | 43,588.58 | 542.40 | -1.23% |
| FTSE 100 | 9,068.58 | 64.23 | -0.70% |
| HKSE | 24,608.64 | 164.69 | -0.66% |
| NASDAQ | 20,650.13 | 472.31 | -2.24% |
| Nikkei 225 | 40,192.24 | 877.58 | -2.14% |
| NZX 50 Index | 12,724.80 | 98.94 | -0.77% |
| S&P 500 | 6,238.01 | 101.38 | -1.60% |
| S&P/ASX 200 | 8,646.80 | 96.00 | -1.10% |
| SSE Composite Index | 3,567.02 | 7.07 | 0.20% |